Wasu harsuna a wannan shafin na iya zama an fassara su da injin kuma suna iya da kurakurai. Help improve it Read the English original
An ga wasu kwayoyin cuta biyu masu launin peach da ke da ƙafafun ganye suna haske a kan wani bango mai duhu, ta hanyar wata fitila.
Red Initiative · Kimiyyar tsufa

Juyar da tsufa: kimiyya

A cikin shekarun da suka gabata, masana kimiyya sun yi kokarin gano yadda za a iya rage yawan mutuwar mutane sakamakon cututtukan da suke haifarwa. Amma har yanzu ba a samu wani abu mai kyau ba.

Snuupo / Wikimedia Commons (CC BY-SA 4.0)

A cikin tarihin, mutane sun mutu suna kanana saboda cututtuka da raunuka da haihuwa. A yau, a cikin mafi yawan duniya, suna mutuwa da tsufa, kuma suna mutuwa daga jerin ƙananan cututtukan da suka fi tsanani: cututtukan zuciya, ciwon zuciya, kwayar cutar kansa, rashin hankali, cututtukan sukari da cututtukan huhu. Ga kõwace daga cikin waɗannan cututtuka akwai ƙwararrunsu, da kyautatawa da magunguna. Amma suna raba wani babban abin da ke haifar da haɗari, kuma ba shan sigari, abinci ko jinni ba ne. Wannan shi ne girma. Wani fanni na kimiyya mai bunkasa, wanda ake kira geroscience, yana tambayar wata tambaya mai sauƙi: a maimakon mu yi yaki da kowace cuta ta tsufa daban-daban, shin za mu iya rage yanayin tsufa da ke tafiyar da su duka? Wannan shafi na bayyana, kamar yadda ya dace da gaskiya da kuma yadda za mu iya, abin da wannan bincike ya nuna, abin da bai nuna ba, da kuma abin da zai iya nufin ga dukkanmu.

8.5 zuwa 9.6 shekaruda yawan shekarun da mutane ke rayuwa cikin rashin lafiya, a duk duniya, 2000 zuwa 2019 (Garmany da Terzic, 2024)
38×da yawa mafi yawan cututtukan zuciya na coronary ne a 75 da sama fiye da a 18 zuwa 44 a Amurka (2025)
$38 trillionda aka kiyasta darajar zuwa Amurka na slowing tsufa isa don ƙara shekara daya na rayuwa tsammani (Scott da sauran, 2021)

Me ya sa tsufa ita ce tushen mafi yawan cututtukan da ke ci gaba

Ka duba kusan kowace cuta mai tsanani ta hanyar shekaru kuma irin wannan siffar zata bayyana: ba ta da yawa a cikin matasa, sa’an nan kuma tana karuwa da sauri tare da kowane ƙarni. A cikin Amurka a 2025, kusan kashi 0.5 na manya masu shekaru 18 zuwa 44 sun kasance an gano su da cutar zuciyar coronary; tsakanin mutane masu shekaru 75 da suka wuce shi ne kashi 19%. Duk wani ciwon daji: kashi 2 bisa dari a kan kashi 33. Artritis: kashi 6 bisa dari a kan kashi 53 cikin dari (NCHS, NHIS 2025). Ana samun karin kamuwa da ciwon daji daga kimanin 236 ga 100,000 mutum a shekara a shekarun 40 zuwa 44 zuwa kimanin 2,400 a 80 zuwa 84 (NCI SEER). Shirin mutane da ke rayuwa da cututtukan zuciya ya ninka kusan sau biyu a kowace shekara biyar zuwa shida bayan 65, yana kaiwa kusan daya cikin uku a shekaru 90 da suka wuce (Manly et al., 2022).

A cikin bayanan Amurka a sama, cututtukan zuciya na coronary suna da yawa fiye da sau 38 a kan 75 da kuma sama da 18 zuwa 44. Wannan shi ne dalilin da ya sa wata ƙungiya ta manyan masu bincike suka bayyana tsufa a matsayin “mafi girman abin da ke haifar da haɗari ga mafi yawan cututtukan da ba a warkewa” kuma sun yi shawara cewa magance tsufa na kansa zai iya jinkirta yawa daga cikinsu (Kennedy et al., 2014). Wannan shi ne gidanka na tattalin ilmi. Kuma akwai wata azãba mai tsanani. Maganin wata cuta ta tsufa yana kara rayuwar mutum kadan, saboda sauran su na jiran magani: mutane da aka ceto daga ciwon zuciya suna fuskantar cutar kansa, ko kuma rashin hankali ko kuma rauni a shekaru kaɗan masu zuwa. Kuma idan ka dakata wa tsufa, to, zã ka mayar da su gabã ɗaya a lokaci guda.

Masu kimiyya sun yi kokarin sanya darajar wannan. Wani bincike na 2013 a Amurka ya gano cewa dakatarwar da ta yi tsawo a cikin tsufa za ta ƙara kusan shekaru 2.2 na fatan rayuwa, mafi yawansu masu lafiya, suna da darajar kusan $ 7.1 trillion a cikin shekaru 50 (Goldman et al., 2013). Wani bincike na 2021 ya kiyasta cewa rage girman gaske don ƙara shekara daya na fatan rayuwa zai zama da daraja $38 trillion to the US, and ten years $367 trillion (Scott, Ellison da Sinclair, 2021). Waɗannan su ne nau’ikan da aka gina a kan zarge-zarge, amma suna nuna dalilin da ya sa gwamnatocin da masu zuba jari suke ba da hankali.

Abin da yake faruwa a gaskiya: alamomin tsufa

Tsanani bai zama hanya guda ba, amma da yawa, suna faruwa tare kuma suna ciyarwa da jũna. A shekarar 2013 wata ƙungiya mai jagorancin Carlos López-Otín ta haɗa su cikin alamomin da ke nuna tsufa tara, kuma a shekarar 2023 ta fadada jerin zuwa goma sha biyu (López-Otín et al., 2013; López-Otín et al., 2023). A cikin magana bayyananna.

  • Genomic instability: damage to DNA builds up faster than it is repaired.
  • Telomere attrition: the protective caps on the ends of chromosomes wear down.
  • Epigenetic alterations: the chemical marks that switch genes on and off drift out of their youthful pattern.
  • Loss of proteostasis: proteins fold wrongly and clump together.
  • Macroautophagy mara aiki: tsarin sake amfani da kwayoyin halitta ya yi sauri.
  • Deregulated nutrient sensing: growth signals such as mTOR and insulin stay switched on when repair would be better.
  • Mitochondrial dysfunction: cell’s power stations make less energy and more harmful by-products.
  • Cellular senescence: damaged cells stop dividing but refuse to die, and release inflammation signals.
  • Stem cell exhaustion: the reserves that repair tissues run down.
  • Saƙonnin da aka canza tsakanin ƙwayoyin halitta: alamun tsakanin ƙwayoyin halitta da organs sun ɓace.
  • Chronic inflammation: wani ƙaramin, ciwon ciki mai tsanani, wanda a wasu lokuta ake kira “inflammageing”.
  • Dysbiosis: the balance of microbes in the gut shifts.

Duk wani tsari a kan wannan shafi yana da nufin daya ko fiye daga cikin waɗannan alamomin. Kuma lalle ne, haƙĩƙa, Allah Ya saukar da wani littafi mai tsarki ga mutãne waɗanda suke sani. Lalle ne, Allah Mai hikima ne, Mai jin ƙai. Wannan gwajin na karshe shi ne inda fatan yake fitowa daga, saboda ga wasu daga cikin waɗannan hanyoyi, masu bincike sun riga sun yi shi a cikin dabbobi.

Shin, mun tabbata? A kan wani ma’auni na shaidar

Kalmar “anti-aging” tana rufe duk wani abu daga halaye da aka tabbatar a cikin miliyoyin mutane zuwa ra’ayoyi da aka gwada a cikin binciken kifi guda. Don a kiyaye su daban, kowace hanya a wannan shafi tana da ɗaya daga cikin matakai huɗu:

  • An tabbatar da shi a cikin mutãne: bincike mai girma na mutum da kuma gwaje-gwajen da aka yi a kan randomized sun nuna cututtuka da mutuwa kaɗan.
  • Promising human trials: randomised trials in people show real effects, but not yet on ageing itself.
  • Strong in animals: repeated, robust results in animals; human evidence small, mixed or just starting.
  • Early ko speculative: mai rauni, da aka yi musu tambayar ko shaidar karatu guda ɗaya, ko kuma gwaje-gwajen mutum har yanzu ba tare da amfanin bayyananne ba.

To be clear: nothing on this page has yet been shown to slow or reverse human ageing as a whole. No drug, supplement or gene therapy is approved to treat ageing anywhere in the world. To, don me ma’abũta ilmi suke yin farin ciki? Saboda shekaru ashirin da suka gabata ba a san wani wanda zai iya fadada rayuwar dabba mai kwakwalwa ta dabi’a da magani ba, kuma yanzu wasu magunguna na yin hakan, a cikin gwaje-gwajen da aka yi la’akari da su a cikin masana’antu daban-daban; saboda za a iya sanya kwayoyin halittar da ke da shekaru suyi aiki kamar waɗanda suke da shekaru kaɗan a cikin kwanon rufi kuma, a cikin wasu ƙwayoyin, a cikin dabbobi masu rai; kuma saboda gwaje-gwajen farko na mutum da aka tsara don nazarin kimiyyar tsufa, fiye da cutar daya, suna gudana a halin yanzu. Hanyar daga kifi zuwa ga mutum mai tsawo ce, kuma mãsu yawa daga hanyoyi mãsu alkawari sun kãsa a kanta. Kuma shiriya bayyananne ce.

Nutrient sensing: mTOR and rapamycin

Evidence grade: promising human trials

Mene ne shi. Duk wani kwayoyin halitta yana da bukatar ya yanke shawarar ko zai girma ko kuma zai gyara kansa. Wani kwayoyin halitta mai suna mTOR (wanda ake kira da ra’ayin mechanistic na rapamycin) yana yin wannan kiran: lokacin da abinci da alamun girma sun yi yawa, mTOR ya ce “ya girma”; Idan sun yi yawa, sai ya koma baya kuma kwayar ta canza zuwa kulawa, ciki har da sake amfani da sassan da suka lalace ta hanyar autophagy. A cikin rayuwarsu ta girma, mTOR na da niyyar zama a kan shiri fiye da yadda yake da kyau ga mu. Kuma lalle ne, haƙĩƙa, Allah Ya saukar da wani littafi mai tsarki ga ManzanninSa, kuma ya sanya su mãsu bãyar da lãbãri.

Rapamycin shi ne magani wanda ke hana mTOR. An gano shi a cikin wani misalin ƙasa daga Rapa Nui (Easter Island), wanda ya ba da sunansa, inda aka yi shi ta hanyar kwayoyin cuta, Streptomyces hygroscopicus (Vézina, Kudelski da Sehgal, 1975). A cikin maganin da aka yi amfani da shi na shekaru da dama don hana jikin mutum ya ki karbar wasu organs.

An yi amfani da wannan don nuna yadda ake yin kwayoyin halitta a cikin kwakwalwa.
Kolonin Streptomyces hygroscopicus a karkashin kwayar ido. Wani nau'in wannan kwayar cuta ta ƙasa, da aka samu a cikin wani misali daga Rapa Nui (Isle of Easter), yana samar da rapamycin, maganin da ke hana mTOR. Photo: Snuupo, CC BY-SA 4.0

Kuma a cikin dabbõbi. A cikin 2009, cibiyar binciken gwajin da aka yi a Amurka ta National Institute on Aging’s Interventions Testing Program, wadda ke gwada sinadarai a cikin kifi masu bambanta da juna a cikin labaran biyu na labaran likitanci a lokaci guda, ta bayyana cewa rapamycin ya tsawaita rayuwar har ma lokacin da aka ba shi a farkon rana 600, ƙarshe a cikin rayuwar kifi. Daga wannan shekarun, tattalin rayuwar ya karu da kashi 28 cikin dari a maza da kashi 38 cikin dari a mata (Harrison et al., 2009). A cikin wani magani mai girma da aka fara a cikin shekarun tsakiyar, adadin rayuwar ya karu da kashi 23 cikin dari a cikin maza da kashi 26 cikin dari a cikin mata (Miller et al., 2014). Rapamycin shi ne maganin da ya fi dacewa a yi amfani da shi wajen rage yawan mutuwar dabbobi, kuma yana daya daga cikin magunguna masu tsawo a duniya.

A cikin mutãne. Wani dalili na mutum ne kaɗan amma gaskiya. A cikin wani bincike na randomized a cikin masu zaman kansu, makonni shida na everolimus, wani ma’aikacin da ke kusa da rapamycin, ya inganta amsawa ga allurar rigakafin kwalara ta kusan kashi 20 (Mannick et al., 2014), kuma wani binciken da ya biyo baya na wani haɗin gwiwar da ke da alaƙa ya rage kamuwa da cuta a cikin shekara mai zuwa (Mannick et al., 2018). Amma wani bincike mai girma na matakin 3 na maganin da ya dace, a cikin mutane sama da 1,000 masu shekaru, bai sami raguwar cututtukan huhu ba (Mannick et al., 2021). A cikin binciken PEARL, an baiwa masu lafiya maganin rapamycin na mako-mako mai ƙarancin kashi a kowace mako na 48 makonni. Ba ta canza ma’auninta na farko, visceral fat, kuma sakamako masu illa sun yi kama da placebo; wasu matakai na biyu, kamar yadda lean muscle a cikin mata akan mafi girman dosi, ya inganta (Moel et al., 2025). A 2024 nazarin 19 bincike ya gano babu wani mummunan al’amari a cikin mutane masu lafiya, amma fiye da cututtuka da mafi girman jini a cikin mutane waɗanda suka riga sun kasance da cutar da ke da alaƙa da shekaru ([Lee, Kuerec da Maier, 2024](https://doi.org/10.1016/S2666-7568(23) 00258-1)).

Risks. A transplant shirye-shirye, rapamycin ya hana tsarin rigakafi da kuma ɗaukar gargaɗi game da cututtuka masu tsanani da wasu kwayoyin cuta. Kuma, a cikinsa akwai wani abu mai kyau da kuma wani abin baƙin ciki.Label). A cikin kifi, amfani mai tsawo yana haifar da juriya ga insulinu (Lamming et al., 2012). Masu bincike suna gwada allurai masu ƙaranci da na lokaci-lokaci, da kuma maganin rigakafi wanda ke hana ɓangaren mTOR kawai wanda ya danganta da tsawon rai.

Senolytics: tsaftace “zombies” cells

Evidence grade: strong in animals

Mene ne shi. Idan wata kwayar halitta ta yi rauni mai tsanani, za ta iya shiga cikin wani hali da ake kira sansenescence: tana daina rabawa, wanda ke kareta daga ciwon daji, amma ba ta mutu ba. Sanin halittu suna ƙãrãwa da tsufa. Worse, they release a cocktail of inflammatory signals, the senescence-associated secretory phenotype (SASP), that harms the healthy cells around them (Coppé et al., 2008). Senolytics sune magunguna da aka tsara don kashe ƙwayoyin cuta na senescent ta hanyar zaɓa.

Hoton microscope biyu a gefe guda: a hagu, kwayoyin halitta masu siffar spindle; a dama, kwayoyin halitta masu girma da ke da launin rawaya-kõre a kusa da nits ɗinsu.
Cells na mouse kafin ( hagu) da bayan ( dama) sun zama senescent. Kwayoyin halittar da ke raye suna girma kuma suna faɗi, kuma sukan juya zuwa launin rawaya-ƙwai tare da wata launi don wani enzyme da suke samarwa a cikin yawa, beta-galactosidase mai alaƙa da rayewar. Ma'aunin bar 100 micrometers. Image: Y tambe, CC BY-SA 3.0

Kuma a cikin dabbõbi. A shekarar 2011, masu bincike sun yi injiniyanci kan kifi don a iya cire kwayoyin halittarsu masu tsufa idan aka bukace su. Clearing them delayed age-related damage in fat, muscle and the eye (Baker et al., 2011). A cikin kifi na yau da kullum, cire waɗannan ƙwayoyin daga tsakiyar shekaru ya rage tsawon rayuwarsu ta kashi 24 zuwa 27 (Baker et al., 2016). An samu farkon hadin maganin senolytic, dasatinib da quercetin, a cikin 2015 (Zhu et al., 2015). An ba da shi ga kwayoyin ƙwayoyi masu tsawo, ya inganta aikin jiki kuma ya ƙara tsawon rayuwar da ke rage da kashi 36 (Xu et al., 2018). Fisetin, wani sinadari na halitta wanda aka samu a cikin strawberries, ya faɗaɗa rayuwar lokacin da aka ba wa kwayoyin ƙwayoyi masu tsawo (Yousefzadeh et al., 2018).

A cikin mutane. Na farko sakamakon mutum ne mai ƙaranci da haɗe-haɗe. A cikin mutane 14 da ke da cutar huhu, fibrosis na huhun idiopathic, makonni uku na dasatinib tare da quercetin sun inganta tafiyar da gudu da sauri, kodayake ba aikin huhu ba, a cikin wani bincike ba tare da rukunin placebo ba (Justice et al., 2019). A cikin mutane tara da ke fama da ciwon sukari na kifi, magunguna sun rage ƙwayoyin cuta a cikin fat da fata kuma sun rage alamun inflammation a cikin jini (Hickson et al., 2019). Amma a cikin wani bincike na kwarara a kan mata masu shekaru 60, magunguna ba su inganta ƙashi ba; kawai matan da suke da mafi yawan ƙwayoyin cuta sun yi kama da amfani (Farr et al., 2024). A cikin wani bincike na yiwuwar a cikin mutane biyar da ke da cutar Alzheimer, dasatinib ya isa ruwa a kusa da kwakwalwa amma quercetin bai yi ba (Gonzales et al., 2023). Mafi girma fisetin gwaje-gwajen a kan Mayo Clinic suna ci gaba da aiki (NCT03675724).

Kamfanin farko da aka gina a kusa da senolytics, Unity Biotechnology, ya gwada allurar ido, UBX1325 (foselutoclax), don cutar ido ta diabetik. Bayan wani bincike na farko mai ban sha’awa, wani bincike na matsakaicin 2 wanda ya kwatanta shi da maganin standard ya rasa manufarsa ta farko (Unity Biotechnology, 2025), kuma kamfanin ya lalace a ƙarshen wannan shekara (SEC filing, 2025).

Risks. Dasatinib shi ne maganin cutar kansa da ke da illa mai tsanani, ciki har da illa ga adadin jini. Sanin sel suna da ayyukan amfani, misali a cikin warkar da rauni, don haka tsaftace su ba tare da haɗari ba ne.

NAD+, NMN and NR

Evidence grade: early or speculative

Mẽne ne ita? NAD+ wani molekiul mai ƙarancin girma ne wanda kowace kwayar halitta ke buƙata don canza abinci zuwa makamashi da kuma gyaran DNA. Yana da matsakaicin zafi, kuma yana da ƙarancin sanyi. An sayar da wasu abubuwa biyu da jikin mutum zai iya juya su zuwa NAD+, nicotinamide mononucleotide (NMN) da nicotinamide riboside (NR), a matsayin kayan haɗin.

In animals. In mice, a year of NMN in drinking water eased several age-related changes, including weight gain and declining energy use (Mills et al., 2016), and NR improved mitochondrial and stem cell function and modestly lengthened life in old mice (Zhang et al., 2016). Amma lokacin da shirin gwajin Interventions ya gwada NR tare da zane mai tsanani, bai fadada rayuwarsa ba a cikin kowane jinsi (Harrison et al., 2021).

A cikin mutane. NR da NMN suna kara NAD+ a cikin jini (Martens et al., 2018). Mafi kyawun binciken da aka sani ya ba NMN ga mata 25 tare da prediabetes na makonni goma: jinkirin insulinin ƙwayar cuta ya inganta da kashi 25 cikin ɗari, yayin da ƙarfin jini, fatar jini da ƙirar jiki ba su canja ba (Yoshino et al., 2021). A cikin wani bincike mai ƙarancin gaske a kan cutar Parkinson, NR ya kara NAD a cikin kwakwalwa tare da ingantacciyar ci gaba ta likita (Brakedal et al., 2022); wani bincike mai girma ya ƙare kuma sakamakonsa ana jiran sa. Reviews that pool the trials so far find the supplements safe in the short term but with mostly no clear benefit for blood sugar, blood fats or muscle (Zhang et al., 2025; Prokopidis et al., 2025). Abin da ba a nuna: cewa haɓaka NAD + yana rage tsufa ko hana kowane cuta a cikin mutane.

Regulation. A cikin 2022, Hukumar Kula da Abinci da Magunguna ta Amurka ta ce NMN ba za a iya sayar da shi ba kamar yadda ake karatun magani; a watan Satumba na 2025 ya juya wannan ra’ayi (FDA, 2025). A kan sayarwa ba ya faɗar komai game da ko wani abu yana aiki.

Sirtuins da resveratrol labarin

Evidence grade: early or speculative

Mẽne ne ita? Sirtuins wani dangin enzymes ne, bakwai a cikin dabbobin jin dadin ci, waɗanda ke amfani da NAD+ don kula da gyara DNA, metabolism da kuma aikin gene. A cikin 2003 wata bincike ya bayyana cewa Name=KDevAdaProject, wani sinadari da aka samu a cikin red zaƙi, activated a sirtuin kuma ya tsawaita rayuwar na ƙwai (Howitz da sauran su, 2003). A cikin 2006 resveratrol ya inganta lafiya da rayuwa na kifi a kan abinci mai yawan calorie (Baur et al., 2006). A shekarar 2008, kamfanin magunguna na GSK ya saya Sirtris, wata kamfani mai haɓaka masu kunna sirtuin, da dala miliyan 720 (GSK da Sirtris, 2008).

Me yasa ya fadi. Labarin bai tsaya da kyau ba. Resveratrol bai kara tsawon rayuwar kifi na yau da kullum ba a kan abinci mai kyau (Pearson et al., 2008), ciki har da shirin gwajin gwaji (Miller et al., 2011). Biochemists sun gano cewa aikace-aikacen bayyananne na sirtuin SIRT1 ya dogara ne akan wata alama ta halitta mai haske da aka yi amfani da ita a cikin gwajin (Kaeberlein et al., 2005; Pacholec et al., 2010). Kuma tasirin rayuwar asali na sirtuin na musamman a cikin ƙwayoyi da kwari ya ɓace sosai lokacin da aka kula da yanayin ilimin halitta (Burnett et al., 2011).

What remains credible. Sirtuins still matter. Kwayoyin da aka tsara don yin fiye da sirtuin guda, SIRT6, sun rãyu tsawon lokaci: maza kawai a cikin binciken farko (Kanfi et al., 2012), kuma a wani bincike na ƙarshe kashi 27 cikin dari mafi tsawo a cikin maza da kashi 15 cikin dari a cikin mata, tare da ƙarancin rauni (Roichman et al., 2021). Wannan ita ce ilimin halitta, ba magani ba ne. Ba a nuna wani ƙari na sirtuin-activating don rage tsufa a cikin mutane ba.

Telomeres and telomerase

Evidence grade: early or speculative

Mẽne ne ita? Telomere su ne sassa masu maimaituwa na DNA da ke rufe ƙarshen kromosomanmu, kamar yadda aka yi da maɓallan plastik a kan ƙafafun takalma. Sunã ragewa da ɗanɗano a kõwane lõkacin da mafi yawan ƙwayoyin ke yin raba; idan sun yi yawa, sai ƙwayar ta hanu daga yin raba ko kuma ta mutu. An yi amfani da telomerase don yin wannan. Elizabeth Blackburn, Carol Greider da Jack Szostak sun raba kyautar Nobel ta 2009 a fannin kimiyya ko likitanci don gano yadda wannan yake aiki (Nobel Prize, 2009).

Kromosomai na mutum masu launin rawaya a kan wani bango mai launin baƙi, kowanne yana da maɓalli masu haske masu launin fari suna nuna telomeres a ƙarshensa.
Kromosoman mutum da telomerensu sun haske da wani fitila mai haske: ƙuƙumma masu haske a kowace ƙarshe. Image: US Department of Energy Human Genome Program, public domain

Kuma a cikin dabbõbi. A shekarar 2012, wata tawaga daga Cibiyar Binciken Kanjamau ta Kasa ta Spain ta ba da maganin halittar kwayoyin halitta ga kifi mai girma wanda ya sake kunna telomerase. Median rayuwa ya karu da kashi 24 cikin dari a cikin kifi da aka yi magani a shekara daya da kuma kashi 13 cikin dari a cikin kifi da aka yi magani a shekaru biyu, ba tare da wani karin a kanjamau (Bernardes de Jesus et al., 2012). Wannan ya ci gaba da zama wani abu mai muhimmanci amma ba a sake yin irinsa ba.

Matsalolin Kansa. Kwayoyin cuta na bukatar su raba kansu ba tare da iyaka ba, kuma mafi yawansu suna yin hakan ne ta hanyar kunna telomerase: a cikin wata bincike mai ban sha’awa, 90 daga cikin 101 na kwayoyin cuta sun kasance masu aiki da telomerase, kuma babu ɗaya daga cikin 50 na ƙwayoyin halitta na yau da kullum (Kim et al., 1994). Mutanen da ke dauke da kwayoyin halittar da suke ba su telomeres masu tsawo suna da haɗarin kamuwa da cututtukan zuciya na coronary amma suna da haɗarin kamuwa da cututtukan kansa da yawa, ciki har da glioma, adenocarcinoma na huhu da melanoma (Haycock et al., 2017). Telomere mai gajeren lokaci ba kawai “masu kyau” ba ne kuma masu tsawo “ma’ana”.

A cikin mutãne. Kuma waɗanda suka yi ĩmãni, su aikata ayyukan ƙwarai, kuma su tsare abin da Allah Ya haramta.Armanios da Blackburn, 2012). A cikin wani bincike a kan waɗannan marasa lafiya, danazolol na hormone ya faɗaɗa telomeres a cikin 11 daga cikin mutane 12 waɗanda za a iya tantance su (Townsley et al., 2016). Wannan shi ne magani ga wata cuta da ba ta da yawa, ba don tsufa ba. Ka yi shakka kan duk wani zargin cewa wani abu ko asibiti “ya fadada telomeres ka” don ya sa ka zama dan karami: a cikin 2015 shugaban wata kamfani ya ce ta samu maganin jinya na telomerase wanda ba a tabbatar da shi ba a waje, amma duk da haka, ba a taba tabbatar da wannan zargi ba a cikin bincike mai nazari (MIT Technology Review, 2015).

Reprograming na ɓangare da ma’aurata Yamanaka

Evidence grade: strong in animals, first human trial under way

Mene ne shi. A shekarar 2006 Shinya Yamanaka ta nuna cewa, sauyawa akan jikoki hudu kawai, yanzu ana kiran su da Yamanaka factors (OCT4, SOX2, KLF4 da c-MYC, ko OSKM), yana mayar da wata ƙwayar fata mai girma zuwa ƙwayar halitta mai kama da kwayar halitta wadda za ta iya zama kowane nau’in ƙwayar halitta (Takahashi da Yamanaka, 2006). Ya raba kyautar Nobel ta 2012 don shi (Nobel Prize, 2012). A kan hanyar, shekarun kwayoyin halitta ana cire su: alamun sinadarai a kan DNA na dawo da wani tsari mai danko. Aikin da ake yi na sake tsarawa ta ɓangare shi ne a kunna ma’aunin kawai cikin ɗan lokaci, mai tsawo da zai iya sake saita alamun shekaru amma ba mai tsawo da zai iya hana sel ya manta da abin da yake.

Shinya Yamanaka a cikin jaka mai launin ruwan kasa, tana tsaye a waje a gaban wata itãciya mai launuka.
Shinya Yamanaka, wanda ya gano cewa jikoki huɗu na iya sake kunna wata ƙwayar halitta mai girma zuwa wani yanayi kamar na kwayoyin halitta, ya buɗe fannin sake tsarawa ta cellular. Photo: Ministry of Education, Culture, Sports, Science and Technology, Japan, CC BY 4.0

Kuma a cikin dabbõbi. A cikin 2016, kifi da ya girma a baya an ba shi OSKM a cikin sifofi, kwanaki biyu da kuma kwanaki biyar. Their organs showed fewer signs of ageing and they lived longer (Ocampo et al., 2016). A cikin 2020, uku daga cikin abubuwan da suka shafi (OSK, barin c-MYC mai alaƙa da kwayar cuta) an aika su zuwa ga idanun kifi tare da rauni mai kama da glaucoma da na kifi masu shekaru, kuma an dawo da ganinsu ta hanyar sake kunna alamun a kan DNA na ƙwayoyin jijiyoyinsu (Lu et al., 2020). Longer-term partial reprogramming in normal ageing mice shifted many molecular markers towards a younger state (Browder et al., 2022), and in one small study, an OSK gene therapy given to very old male mice doubled their remaining median lifespan (Macip et al., 2024).

A round, densely packed colony of cells glowing magenta, violet and green on a black background.
Wani sansanin kwayoyin halittar pluripotent na mutum, wanda aka yi ta hanyar sake tsarawa ga kwayoyin cutar kansa da abubuwan Yamanaka, an shafa shi ne don gina wasu sinadarai da ake samu kawai a cikin kwayoyin halitta. National Eye Institute, NIH, mallakar jama'a

Risks. Going too far is dangerous. A lokacin da aka kunna abubuwan a hankali a cikin kifi mai rai, kwayoyin sun rasa alamunsu kuma suka samar da kwayoyin cuta masu suna teratomas (Abad et al., 2013); a wata bincike ta daban, OSKM na ci gaba ya haifar da rashin lafiyar jijiya da ƙwayar ciki da mutuwar cikin mako guda (Parras et al., 2023). Kula da adadin, lokacin da kuma waɗanne ƙwayoyin halitta ke karɓar waɗannan jinni shine babban kalubale.

Dakunan gwaje-gwajen da farko. Sashe na sake tsarawa ya jawo wasu daga cikin manyan saka hannun jari a cikin fasahar halittu. Altos Labs an fara shi a watan Janairu 2022 da $3 billion (Altos Labs, 2022). Retro Biosciences, backed with $miliyoyin 180 ta Sam Altman (MIT Technology Review, 2023), yana aiki kan sake tsarawa kuma ya ce maganinsa na farko, wani magani wanda ke nufin sake amfani da ƙwayoyin cuta, ya shiga wani matakin 1 na binciken a shekarar 2025 (Retro Biosciences, 2026). NewLimit ya tara dala miliyan 435 a shekarar 2026 kuma ya ce yana shirin yin nazarin farko na mutum na maganin ciwon daji (NewLimit, 2026). Maganin farko na sake tsarawa don isa ga mutane shine ER-100 daga Life Biosciences, wata maganin OSK gene da aka zuba a cikin ido don cututtukan biyu na nerve optic, glaucoma da non-arteritic anterior ischaemic optic neuropathy (NAION). Hukumar Kula da Abinci da Magunguna ta Amurka ta tabbatar da bincike a watan Janairu 2026 (Life Biosciences, 2026), kuma mai cutar farko an yi masa magani a watan Yunin 2026 a cikin binciken tsaro na matakin 1 na mutane 18 (ClinicalTrials.gov NCT07290244; Life Biosciences, 2026). Zai dauki shekaru.

Sauran manyan hanyoyi

Name=Dabarun da ke faɗaɗa rayuwar kifin

Evidence grade: strong in animals

Tun daga 2004, shirin gwajin Interventions ya gwada sinadarai 54 a cikin kifi fiye da 30,000 (Jiang et al., 2025). Tsarinsa mai tsauri ne: irin wannan gwajin yana gudana a cikin labaratoci uku, tare da kifi masu bambanta ta halitta, don haka sakamakon ya kamata ya tsaya a cikinsu duka. A gefen rapamycin, wasu sinadarai sun wuce: maganin ciwon sukari acarbose ya kara kashi 22 cikin dari ga tsawon rayuwar namiji amma kashi 5 cikin dari kawai a cikin mata (Harrison et al., 2014); 17-alpha-estradiol, wani nau’in estrogen mai rauni, ya ƙara kashi 19 cikin dari a cikin maza kuma babu komai a cikin mata (Strong et al., 2016); da maganin ciwon sukari canagliflozin ya ƙara kashi 14 cikin dari a cikin maza kawai (Miller et al., 2020). Rapamycin tare da acarbose ya ba da mafi girman riba har yanzu: kashi 34 cikin dari a cikin maza da kashi 28 cikin dari a cikin mata (Strong et al., 2022). Me ya sa maza ke amfana da wannan a mafi yawan lokuta shi ne wata tambaya mai muhimmanci. Ba a yi gwajin kowace daga cikin wadannan magunguna ba ga masu tsufa a cikin mutane.

Kwayoyin kwayar halitta masu launin shuɗi uku a kan takardar da aka yanka ta cikin wani ɗaki, a kusa da wani tushe na karfe.
Kwayoyin kwayar halittar da aka yi amfani da su a cikin binciken sun kasance suna rayuwa ne kawai tsawon shekaru biyu zuwa uku, wanda ya baiwa masu bincike damar yin nazarin tasirin maganin a kan rayuwar mutum gaba ɗaya a cikin shekaru kaɗan. An yi gwajin kowace hanya a kan wannan shafi a cikin kifi kafin mutane. Photo: Understanding Animal Research, CC BY-SA 4.0

Metformin and the TAME trial

Evidence grade: early or speculative

Metformin shi ne maganin cutar sukari mai arha da aka yi amfani da shi na fiye da shekaru sittin. A 2014 bincike na UK records lafiya gano cewa mutane da suka yi fama da ciwon sukari rike metformin rayuwa kaɗan fiye da daidaita mutane ba ciwon sukari (Bannister et al., 2014), wanda ya sa shi wani shugaban takarar ga anti-aging magani. An tsara binciken TAME (Targeting Aging with Metformin) don gwada ko yana jinkirta cututtukan zuciya, kwayar cutar, rashin hankali da mutuwar tare a cikin masu shekaru, kuma don yaudarar masu kula da su yi la’akari da tsufa kamar wani abu ne da magani zai iya shafar (Barzilai et al., 2016). A watan Satumba na 2026 ba mu iya samun sakamakon da aka wallafa ba. A cikin wannan lokacin, lamarin ya yi rauni: wani bincike na Denmark wanda ya haɗa da ‘ya’yan biyu bai gano wata dama ba ta rayuwa ga masu amfani da metformin (Keys et al., 2022); metformin kadai bai fadada rayuwar kifi ba a cikin shirin gwajin Interventions (Strong et al., 2016); kuma a cikin gwaje-gwajen biyu a cikin manya masu shekaru ya rushe amfanin horar da motsa jiki (Konopka et al., 2019; Walton et al., 2019).

GLP-1 medicines

Evidence grade: promising human trials

Waɗannan ƙwayoyin cuta suna dauke da wani sinadari mai suna GLP-1, wanda ke hana ciwon sukari da kuma nauyi. A cikin binciken SELECT na mutane 17,604 da ke fama da ciwon ciki da cutar zuciya, semaglutide ya rage kamuwa da cututtukan zuciya, raunuka da mutuwar jijiyoyin jini da kashi 20 (Lincoff et al., 2023). Wani bincike na Amurkawa masu fama da ciwon sukari ya danganta GLP-1 magani ga rage haɗarin halaye da yawa, ciki har da rashin hankali, sha’awa da cututtuka, da kuma ƙarancin haɗarin wasu, kamar matsalolin ciwo da ciwon pancreas (Xie, Choi da Al-Aly, 2025), amma irin waɗannan nazarin binciken ba za su iya tabbatar da dalili ba. Kuma a cikin gwaje-gwajen biyu masu girma a farkon cutar Alzheimer, Semaglutide na magana bai rage asarar ba (Cummings et al., 2026). Waɗannan ne magunguna mãsu ƙarfi ga cututtuka na musamman; ko kuwa su kange tsũfawa kansu ba a sani ba.

Calorie restriction

Evidence grade: promising human trials

Abincin kaɗan ba tare da rashin abinci ba yana faɗaɗa rayuwar nau’ikan halittu da yawa, kuma shi ne farkon “haɗin gwiwar anti-aging” da aka taɓa samu. A cikin tsuntsaye, manyan bincike biyu masu tsawon lokaci a farkon sun yi kama da rashin yarda, amma wani nazari mai haɗin gwiwa ya yanke shawarar cewa hana calorie yana inganta lafiya da rãyuwa idan an ɗauki bayanin abinci da shekaru (Mattison et al., 2017). A cikin CALERIE 2 bincike, 218 lafiya, non-obesitas mutane aka tambaye su su ci 25 bisa dari kaɗan ga shekaru biyu da kuma gudanar da kusan 12 bisa dari. Yawan jininsu, cholesterol da kuma jin dadin insulin sun inganta (Kraus et al., 2019), kuma wani ma’aunin gudun tsufa na halitta, DunedinPACE, ya raguwa da kashi 2 zuwa 3 cikin dari, kodayake wasu biyu ba su canja ba (Waziry et al., 2023). Rashin cin abinci mai gina jiki na iya haifar da rashin lafiyar jijiyoyi da ƙashi, kuma ba shi da aminci ga mutane masu cutarwa ko wadanda ke cikin hadarin kamuwa da cututtukan ciwon ciki, ko kuma ga matasa marasa lafiya.

Dabaru na musayar jini da plasma

Evidence grade: early or speculative

Idan an haɗa jijiyoyin kifi mai tsufa da kuma kifi mai ƙarancin shekaru, wasu daga cikin ƙwayoyin kifin da suka tsufa, kamar su ƙwayar jiki da kuma ciwon zuciya, suna gyara kansu mafi kyau (Conboy et al., 2005). An yi kira ga wani protin jini, GDF11, a matsayin abin da ke rage shekarun, amma aikin da ya biyo baya bai iya samar da sakamakon ba (Egerman et al., 2015). Wasu masu bincike yanzu suna tunanin cewa rage abubuwan da ke haifar da illa a cikin jinin da ya wuce shekarunsa yana da muhimmanci fiye da ƙarawa da waɗanda suke da shekaru: a cikin kifi masu shekaru, kawai sake maye gurbin rabin plasma tare da madara da magungunan albumin sun inganta ƙwayoyin jiki, ƙwayar zuciya da kuma kwakwalwa (Mehdipour et al., 2020). A cikin wani bincike mai ƙarancin placebo-controlled, sake maimaita therapy plasma exchange (sauya plasma da magungunan albumin) ya canja wasu wayoyin epigenetic zuwa ga wata shekara mai ƙaranci (Fuentealba et al., 2025), kuma a cikin wani binciken cutar Alzheimer’s ya rage raguwa a cikin ayyukan yau da kullun a cikin mutane masu cutar ta tsanani (Boada et al., 2020). A cikin 2019, Hukumar Kula da Abinci da Magunguna ta Amurka ta gargadi jama’a cewa infusions na plasma daga masu bada gudummawa matasa ba su da “farashin likitan da aka tabbatar” kuma suna ɗaukar haɗarin gaskiya (FDA, 2019).

Epigenetic clocks: measuring biological age

A kayan aiki na auna, ba wani magani

Don gwada ko wani abu na daure tsufa, masu bincike suna buƙatar hanyar auna shi ba tare da jira shekaru goma ba. Epigenetic clocks karanta alamun sinadarai (methylation) a ɗaruruwan wurare akan DNA kuma su kiyasta shekaru daga siffar. Na farko, daga Steve Horvath, ya yi aiki a kan dubban kwayoyin halitta (Horvath, 2013; Hannum et al., 2013). Bayan haka aka horar da wayoyin salula don yin hasashen lafiya fiye da shekarun kalanda: PhenoAge (Levine et al., 2018), GrimAge, wanda ke nuna lokacin mutuwar (Lu et al., 2019), da DunedinPACE, wanda ke kiyasta yadda sauri mutum yake tsufa yanzu, kamar mai sarrafa gudu (Belsky et al., 2022). Waɗanda suke da agogo suna tafiya a gaban shekarunsu suna mutuwa cikin sauri (Chen et al., 2016).

Abin da ba za su iya gaya mana ba: ko juyawa agogo baya zai sa mutum ya fi lafiya. Magani zai iya canja alamomin ba tare da canja halittar dake karkashinsu ba. Agogo na iya zama mai zafi: irin wannan misalin jini wanda aka auna sau biyu ya ba da karatu har zuwa shekaru tara, kodayake siffofin ingantattu sun rage wannan (Higgins-Chen et al., 2022). “Yara na halitta” gwaje-gwajen masu amfani suna da bambanci sosai kuma ba za su iya shirya shawarwari na likita ba.

Abin da aka tabbatar a yau a cikin mutane

Evidence grade: proven in people

A yayin da kimiyya ke ci gaba, mafi ƙarfin shaidar shekaru masu lafiya suna zuwa daga halaye da magani waɗanda aka gwada a cikin yawan mutane mai yawa. Kuma bãbu wanda yake jinkirtar da tsufa daga gare su, kuma amma suna jinkirta wa mutuwa shẽkaru, kuma mafi yawansu sunã kashe kaɗan kõ kuwa bãbu kõme.

Aiki na jiki. Kungiyar Lafiya ta Duniya tana shawartar minti 150 zuwa 300 na aiki mai tsanani, ko kuma minti 75 zuwa 150 na aiki mai karfi, a duk wata, tare da ƙarfafa ƙwayoyin jiki a cikin kwanaki biyu ko fiye da haka, kuma ga masu girman shekaru, horar da daidaito don hana faɗuwa. Aikin da ake yi a kullum yana da alaka da rage hadarin kamuwa da cututtukan zuciya, ciwon zuciya, cututtukan sukari na nau’i 2, cututtukan kansa da dama, rashin lafiyar zuciya da kuma rashin hankali (WHO, 2020). Kuma, lalle ne, haƙĩƙa, Allah Mai hikima ne, Mai jin ƙai.

Wata mata mai shekaru da ke murmushi a cikin jakar rawaya, kafada da linzami tana tafiya a kan hanya mai hasken rana.
Kuma tafiya mai sauƙi a cikin gaggawa tanã lissãfi dõmin aikin ƙwarai. WHO ta shawarci a kalla minti 150 na shi a mako, ko kaɗan idan yana da ƙarfi. Photo: US National Cancer Institute, public domain

Ba ta shan sigari. Mutanen da suka daina shan sigari kafin shekaru 40 suna kauce wa fiye da kashi 90 na haɗarin mutuwar da ke faruwa daga ci gaba (Jha et al., 2013). Ya hana a duk wani rãyuwar taimako.

Abubuwan da suka shafi jini da cholesterol. A cikin binciken SPRINT, kulawa mai tsanani na jini ya rage abubuwan zuciya da mutuwar, kuma ya rage rashin fahimtar sauki (SPRINT MIND, 2019). Ciwon jini mai tsanani ba ya nuna alamun cututtuka, don haka auna shi shine hanya daya tilo da za a iya sani.

Hannun mutum a cikin wani riga mai buɗewa wanda aka haɗa da wani mai kula da zafin jini na atomatik akan tebur.
A gwajin jinin a gida da wani auto cuff. Ciwon zuciya mai tsanani ba ya haifar da alamun cututtuka, don haka auna shi shine hanya daya tilo ta sani. Photo: Beendy234, CC0

Diet. A cikin binciken PREDIMED, abincin Mediterranean wanda aka cika da man zaitun ko nutsan ya rage manyan abubuwan zuciya da kashi 30 idan aka kwatanta da abinci mai ƙarancin fat (Estruch et al., 2018). WHO ta ce babu wani mataki na shan giya da yake amintacce ga lafiya; kaɗan ya fi kyau.

Sleep. Matasa ana shawartar su da su yi barci na tsawon sa’o’i bakwai a dare ta hanyar (Watson et al., 2015); barcin da ya yi tsawo ko kuma wanda aka shafa yana da alaka da ciwon zuciya da kuma cututtukan metabolism, kuma apnea na barci yana da yawa kuma ana iya magance shi.

Haɗin jama’a. A cikin wani babban meta-analysis, mutane da karfi dangantaka na zamantakewa sun kasance kusan 50 bisa dari mafi girman yiwuwar rayuwa a kan lokacin bincike (2010).

Jin, gani da allurai. Rashin jin shine mafi girman ma’aunin haɗarin canzawa na mutum don rashin hankali wanda aka sani ta Hukumar Lancet, wacce ke haɗe kashi 45 cikin dari na lokutan rashin hankali zuwa ma’aunin 14 masu canzawa (Livingston et al., 2024). A cikin binciken ACHIEVE, wani mataki na sauraro ya rage asarar fahimta da kashi 48 cikin dari a cikin shekaru uku a tsakanin masu tsufa masu haɗari (Lin et al., 2023). Wani bincike na halitta a Wales ya gano cewa rigakafin shingles an bi shi da kashi 20 cikin dari kaɗan na gwaje-gwajen rashin hankali a cikin shekaru bakwai (Eyting et al., 2025).

Wani rukuni na mutane masu shekaru suna yin aiki da tai chi tare a kan hanya mai ratsawa da kogin a karkashin bishiyar cherry.
Tai chi a karkashin inuwar cherry a kan tekun Okawa a Osaka, Japan. Motsa tare yana kawo aiki da kamfani a cikin lokaci guda. Photo: m-louis, CC BY-SA 2.0

A lokacin da wuraren ke canjawa. Mafi girman nasarori sun zo ne a lokacin da al’umma suka canja tare. A Arewacin Kareliya, Finland, wani shirin yanki-da-yanki daga 1972 ya rage shan sigari, cholesterol da kuma zafin jini, da mutuwar cututtukan zuciya a tsakanin mutane masu shekaru 35 zuwa 64 sun fadi da kashi 82 cikin dari a cikin maza da kashi 84 cikin dari a cikin mata a shekarar 2012 (Jousilahti et al., 2016; Puska et al., 2016). Bayan da Scotland ta haramta shan sigari a wuraren jama’a masu kulle a cikin 2006, asibitocin asibitoci don harin zuciya da kuma angina mai rashin daidaito sun fadi da kashi 17 cikin dari a cikin shekara (Pell et al., 2008). A cikin binciken FINGER na Finland, wani shirin shekaru biyu na abinci, motsa jiki, horar da kwakwalwa da kuma duba jijiyoyin jini ya inganta tunani da tunawa a cikin mutane masu haɗarin kamuwa da cuta (Ngandu et al., 2015), kuma a Taketoyo, Japan, mutanen da suka fi girma waɗanda suka halarci salons na jama’a sun kasance kusan rabin yiwuwar samun rashin iya aiki a cikin shekaru biyar (Hikichi et al., 2015).

Mafi ƙarfin mafita na tsawon rai da aka yi gwaji a baya ba su da tsada: motsa jiki, barci, kada ku sha giya kuma ku kasance masu haɗin kai. Kuma ilmin zamani mai kyau yana nufin ya ƙãra musu, bã ya musanya su.

Yadda rayuwar lafiya mai tsawo za ta canza al’umma

Duniya tana fuskantar wani canji na jama’a wanda bai taba faruwa ba a baya. Bisa ga Majalisar Dinkin Duniya, adadin haihuwar duniya yanzu shine 2.25 na haihuwar mace daya, ya sauka daga 3.31 a cikin 1990; fiye da rabin dukkan kasashen da yankuna suna da yawan haihuwa a ƙasan matakin maye gurbin kusan 2.1, kuma kusan ɗaya cikin biyar yana ƙasa da 1.4. Yawan jama’ar duniya, 8.2 biliyan a cikin 2024, ana tsammanin zai kai kusan 10.3 biliyan a cikin tsakiyar 2080s kuma ya fadi kadan zuwa 10.2 biliyan ta hanyar 2100. A cikin kasashe da yankuna 63, masu rike da kashi 28 na al’ummar duniya, yawan jama’a ya kai ga mafi girma. A ƙarshen 2070s, mutane masu shekaru 65 da sama ana tsammanin za su fi yawan yara waɗanda ke ƙasa da shekara 18 (UN World Population Prospects 2024). Dalilin da ya sa yawan haihuwa ke karuwa, da kuma dalilin da yasa Local Solar System Foundation take goyon bayan ilimi da zaɓi na gaskiya ga kowace iyali, an bayyana su a shafinmu na population, consumption and resources.

A kan bayyana yawan jama’a mai shekaru da yawa a matsayin nauyi: ma’aikata kaɗan suna tallafawa masu ritaya da yawa. Ma’aunin ma’aunin, rashin dogaro da shekaru, yana lissafa mutane masu shekara 65 da sama ga kowane mutum 100 masu shekaru 20 zuwa 64. An kiyasta daga adadin Majalisar Dinkin Duniya, ya kasance 18 ga duniya a cikin 2024 kuma ana hasashen zai kai 29 a cikin 2050 da 44 a cikin 2100; a Japan yana da shekaru 55 (UN World Population Prospects 2024).

“Tsãwa bã ta zama adadi mai ƙayyadaddun lõkatai ba.”

Wannan adadi ya yi zato cewa mutum mai shekaru 65 a shekarar 2100 zai zama kamar wanda yake da shekaru 65 a shekarar 1950. Masu nazarin al’umma Warren Sanderson da Sergei Scherbov sun yi zargin cewa wannan yana haifar da kuskure. Sun yi shawara kan a auna shekarun da mutane suka bar su rãyu, ba shekarun da suka rãyu ba, kuma sun nuna cewa jama’a na iya “rayuwa mai kyau” ta wannan mataki har ma da lokacin da yawansu ya karu (Sanderson da Scherbov, 2005; Sanderson da Scherbov, 2010). Wani nau’i na ƙayyade iyakar shekarun da ake tsammani na rayuwa ya ragu zuwa kasa da shekaru 15: ga mata masu Faransanci, wannan ya kasance 58 a cikin 1900 kuma kusan 75 a cikin 2012 (Sanderson da Scherbov, 2015).

Kalmar maɓalli healthy ce. A fadin duniya, tattalin arzikin rayuwa ya karu daga shekaru 66.8 zuwa 73.1 tsakanin 2000 da 2019, yayin da bambancin tsakanin tattalin arzikin rayuwa da tattalin arzikin rayuwar lafiya ya fadada daga shekaru 8.5 zuwa 9.6 (WHO Global Health Observatory; Garmany da Terzic, 2024). Wasu shekarun da ake kashewa a cikin rashin lafiya suna kara wa iyalai da tsarin kiwon lafiya na kasar nan matsaloli. Shekaru masu yawa a cikin lafiya mai kyau suna da bambanci: mutane za su iya ci gaba da aiki idan sun so, kula da wasu, yin aikin hajji, koyon abubuwa da kuma bayar da gudummawa. Wannan shi ne dalilin da ya sa kimiyya a kan wannan shafi tana da muhimmanci ga jama’a, ba kawai ga mutane ba.

Wannan shi ne misali, ba wani hasashe ba. Ta yi amfani da adadin jama’ar da Majalisar Dinkin Duniya ta yi hasashensu kuma ta tambayi wata tambaya: idan mutane suka samu shekaru masu lafiya da kuma shekarun da suke da su na daina aiki kuma suna bukatar karin goyon baya sun tashi tare da su, yaya za a canza daidaito? Idan wannan layin ya motsa daga 65 zuwa 70, duniyar shekarar 2100 za ta sami mutane 31 masu shekaru ga kowanne mutum 100 na shekara mai aiki a matsayin 44; a shekara ta 75, kusan 21, kusa da matakin yau. An yi zaton cewa shekarun da aka kara suna da kyau, cewa aikin yi da kuma biyan albashi na iya canjawa, kuma cewa riba ta kai ga kowa, ba ma masu arziki kawai ba.

Bayan haka, lafiyar iyaye

Waɗannan uwayen suna da ‘ya’ya a wani lokaci na ƙarshe a kusa da dukansu. A cikin kasashen OECD, yawan shekarun uwaye a lokacin haihuwarsu ta farko ya karu daga 26.4 a shekarar 2000 zuwa 29.6 a shekarar 2024 (OECD Family Database). Ma’aurata suna nuna alamun tsufa a farkon lokacin da suke da yawa fiye da sauran tishu a cikin jiki (Garrison, 2026), kuma rashin haihuwa a ƙarshen shekaru goma sha uku da arba’in yana iya hana yawan yara da mutane waɗanda suka fara bayan haka za su iya samun. Binciken kan tsufa mai yawa yanzu ya zama wani bangare na geroscience: misali, binciken VIBRANT a Jami’ar Columbia ya gwada ko rage adadin rapamycin zai iya rage rasa ƙwai a cikin mata masu shekaru 35 zuwa 45 (ClinicalTrials.gov NCT05836025); sakamakonsa bai fito ba har yanzu. Idan za a iya rage tsananin tsufa na haihuwa, mutane da suke so su sami yara za su iya yin hakan nan gaba, ba tare da wani yunkuri na rufe kofar ba.

Me ya sa masu nazarin jama’a ke tsammanin karuwar za ta ci gaba

Yana da muhimmanci a kasance gaskiya game da ra’ayin maƙiyi. The Global Burden of Disease forecasters expect 155 of 204 countries and territories to have fertility below replacement by 2050 and 198 by 2100; Daga cikin 47 kasashen da yawan haihuwa ya karu, guda uku ne kawai suka dawo a sama da canjin (GBD 2021 Fertility and Forecasting Collaborators, 2024). Majalisar Dinkin Duniya ta yanke hukunci cewa kasashen da ke da yawan haihuwa mai yawa wadanda al’ummarsu ta kai ga mafi girma ba za su iya dawowa zuwa canji ba cikin shekaru 30 (UN World Population Prospects 2024). Wasu masana demography sun bayyana wani mummunan matsayin ƙarancin haihuwa, wanda a ciki ƙarni masu ƙaranci, ƙananan girman iyali da matsin tattalin arziki suna ƙarfafa juna (Lutz, Skirbekk da Testa, 2006), kuma masana kimiyya na tattalin arziki Dean Spears da Michael Geruso sun yi zargin cewa ba tare da canji ba, yawan jama’ar duniya zai iya raguwa har tsawon lokaci bayan ya kai mafi girmansa (Spears da Geruso, 2025). Rayuwa mai tsawo ba ta warware wannan ba: suna raguwa da sauri, amma a cikin lokaci mai tsawo, yawan jama’a wanda yake da yawa kaɗan yana ci gaba da ragewa.

Matsayinmu: rashin daidaituwa matsala ce ta lokaci

Dakata Local Solar System Wannan shi ne dalilin da ya sa aka yi wannan hukunci. QOCIResult, wani canji don daidaita zuwa a maimakon wani cikas na dindindin. Munã gabatar da wannan a matsayin zance, tare da dalilanmu da hujjõji waɗanda ke tabbatar da shi ko kuma ba haka ba.

A’a, sunã da wata hujja.

  1. Yawan rayuwa mai lafiya yana nufin akwai bukatar haihuwar yara kaɗan don samun adadin jama’a mai daidaito. A cikin jama’a da ba su girma ko kuma suka yi kasa, girmansu ya daidaita da adadin haihuwa a kowace shekara wanda aka ninka shi da tattalin arzikin rayuwa a lokacin haihuwa, wata alamar farko ta demography (Preston, Heuveline da Guillot, 2001). Idan an samu karuwar tattalin arziki daga kusan shekaru 73 zuwa 90, za a iya kiyaye yawan jama’a da kashi biyar na adadin haihuwar da ake samu a kowace shekara.
  2. Lafiya, ba shekarun ba, ita ce ke tantance wanda yake bukatar taimako. Idan ilimin zamantakewar mutum ya dakatar da cututtukan da suka shafi shekaru har zuwa shekaru kadan, to adadin dogaro na iya zama kusa da na yau duk da cewa jama’a suna girma, kamar yadda hoton sama ya nuna.
  3. A tsawo da haihuwa window za a iya barin mutane su sami yara da suke so. Idan haihuwa tsufa za a iya rage da aminci, bayan haihuwa ba zai zama nufin yara kaɗan.
  4. Fertility has recovered before. Among the most developed countries, some studies found that further progress in development was associated with rising fertility (Myrskylä, Kohler and Billari, 2009), especially where work and family life are easier to combine (Luci-Greulich and Thévenon, 2014), though this finding is disputed (Harttgen and Vollmer, 2014).
  5. A mai da hankali ga ragewa yana ba da lokaci don canjawa. Majalisar Dinkin Duniya tana hasashen karuwar sauri da kuma karuwa a wannan karni, ba tashin hankali ba, wanda ke barin shekaru da dama domin ci gaban kimiyya, aiki da kuma dokar iyali don canjawa.

Me zai yi gwajinsa? Sanarwar za ta samu goyon baya idan: tattalin rayuwar lafiya ya tashi da sauri fiye da tattalin rayuwa, yana rufe ɓangaren; wani bincike ya nuna cewa wata hanyar shiga tana jinkirta cututtukan shekaru da dama a lokaci guda, kamar yadda TAME aka tsara don yin hakan; haihuwar a cikin shekaru masu girma sun karu sosai don haka yawan iyalai ya daina faduwa; kuma hasashen dogaro ga shekarun da suka wuce wanda aka kiyasta ta hanyar lafiya, maimakon ta hanyar shekaru masu daidaituwa, suna zama masu daidaito. Za ta yi rauni idan bambancin shekaru masu lafiya ya ci gaba da fadada, idan gwaje-gwajen farko na rapamycin, senolytics da sake tsarawa sun kasa, kuma idan yawan haihuwar ya ci gaba da raguwa har ma inda iyaye ke da rayuwar lafiya mai tsawo, goyon baya mai kyau da zaɓi na gaskiya. Za mu bi da shaidar kuma mu sabunta wannan shafi kamar yadda ya zo.

Duniya mai yawan mutane kaɗan da suke rayuwa tsawon lokaci za ta iya zama wata duniyar da take da haske, wannan shi ne dalilin da ya sa wannan tambaya ke da alaƙa da aikin Local Solar System Foundation a kan hadin kai tsakanin mutane da albarkatu.

Yi hankali: kayan haɗi, asibitoci da gwajin kanka

Organizers doing this work

Waɗannan kungiyoyi masu zaman kansu suna wallafa abin da suke yi kuma suna bayar da rahoton sakamakon da za a iya auna su. Idan kana so ka tallafawa matasa masu lafiya, to ka duba aikinsu kuma ka yi tunani kan bayar da gudummawa gare su kai tsaye, ta hanyar shafukan yanar gizo na su. Dakata Local Solar System Bã ya da wata zumunta da kõwa daga gare su. Kuma bã ya karɓar kõme daga gare su. A gabãnin ka bã su, ka karanta dukkan ƙungiya’s nata rahoton shekara-shekara da kuma asusun.

  • HelpAge International (United Kingdom, registered charity 288180). Yana aiki tare da kungiyoyi masu hadin gwiwa a kasashen da dama don haka mutanen da suka wuce shekarun su sami damar samun kulawar lafiya, kulawar zamantakewa da tsaron kudin shiga, kuma yana magana game da hakkinsu.
  • Age UK (United Kingdom, registered charity 1128267). Yana bayar da goyon baya ga masu shekaru masu fama da talauci, tsare-tsaren da kuma rashin kulawa, da bincike da kamfen don inganta tsarin.
  • British Heart Foundation (United Kingdom, registered charity 225971). The largest independent funder of research into heart and circulatory disease in the United Kingdom. (a cikin Ingilishi)
  • American Heart Association (United States, tax-exempt non-profit). Ya na bada tallafi ga bincike a kan cututtukan zuciya da ciwon zuciya, kuma yana gudanar da shirye-shiryen jama’a kan hana kamuwa da su.
  • Alzheimer’s Society (United Kingdom, registered charity 296645) da kuma Alzheimer’s Association (United States, tax-exempt non-profit). Dukkansu suna goyon bayan mutane da ke rayuwa da cututtukan zuciya da masu kula da su, kuma suna tallafawa bincike a kan hanawa, magani da kulawa.

Yadda zaka iya taimaka

  • Ku yi farawa da abin da aka tabbatar. Ka yi tafiya kaɗan a yau, ka ƙara ƙarfi da daidaitattun motsa jiki, kuma ka tambayi wani masanin lafiya ya duba zafin jininka.
  • Ya yi gwajin jinka da ganinka, kuma ya yi wa mahaifiyarka da ubanninka gargadi su yi kama da haka.
  • Ka ci gaba da kasancewa cikin haɗin kai. Ka kira wani wanda ba ka yi magana da shi ba na ɗan lokaci; Ka kira wani maƙwabci mai nisa zuwa wani abu.
  • Ka bi gwaje-gwajen, ba tallace-tallace. Amsoshin daga gwaje-gwajen da aka yi rajista, an wallafa su a cikin littattafai masu nazari, sune abin da ke da muhimmanci.
  • Ka yi shakka game da zargin mu’ujiza, kuma ka raba wannan shafi idan ka ga daya.
  • Ku taimake mu mu kiyaye wannan shafi daidai. Masu bincike, likitoci da mafatanci za su iya yin aiki na kyauta a kan tashar tallafi.

Sources and further reading